Prof. Dr. İBRAHİM YILDIZ

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.20, sa.4, ss.1015-22, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

40. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer.

Vedat Bayoglu I., Yildiz İ., Varol U., Cokmert S., Kucukzeybek Y., Alacacioglu A., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.20, sa.2, ss.460-7, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

41. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Bayoglu I. V., Kucukzeybek B. B., Kucukzeybek Y., Varol U., Yildiz İ., Alacacioglu A., et al.

BIOMEDICINE & PHARMACOTHERAPY , cilt.70, ss.190-195, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

42. Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma

Sen F., Yildiz İ., Odabas H., Tambas M., Kilic L., Karadeniz A., et al.

TUMOR BIOLOGY , cilt.36, sa.2, ss.1039-1044, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

43. The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study

Akyol M., Demir L., Alacacioglu A., ELLİDOKUZ H., Kucukzeybek Y., Yildiz Y., et al.

CHEMOTHERAPY , cilt.61, sa.2, ss.57-64, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

44. Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study

Bayoglu I. V., Yildiz İ., Varol U., Cokmert S., Alacacioglu A., Kucukzeybek Y., et al.

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY , cilt.19, sa.5, ss.385-390, 2015 (ESCI, Scopus) Sürdürülebilir Kalkınma

45. Adjuvant chemotherapy and prognostic factors in stage II colon cancer - Izmir oncology group study

Kucukzeybek Y., Dirican A., Demir L., Yildirim S., Akyol M., Yildiz Y., et al.

Asian Pacific Journal of Cancer Prevention , cilt.16, sa.6, ss.2413-2418, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

46. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients

Kilic L., YILDIZ İ., Sen F. K., Erdem M. G., SERİLMEZ M., Keskin S., et al.

CANCER BIOMARKERS , cilt.15, sa.4, ss.405-411, 2015 (SCI-Expanded, Scopus)

47. Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.

Yildiz İ., Varol U., Sen F., Kilic L.

Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology , cilt.14, sa.7, ss.654-6, 2014 (SCI-Expanded, Scopus, TRDizin)

48. Clinical significance of serum M30 and M65 levels in patients with breast cancer

TAŞ F., KARABULUT S., YILDIZ İ., DURANYILDIZ H. D.

BIOMEDICINE & PHARMACOTHERAPY , cilt.68, sa.8, ss.1135-1140, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

49. Gastric cancer with diffuse hepatic metastases and complete radiological response to triplet chemotherapy

Varol U., Alacacioglu A., Yildiz İ., Kucukzeybek Y., Uslu R.

JOURNAL OF BUON , cilt.19, sa.4, ss.1128-1129, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

50. Assessment of the Quality of Life in Turkish Breast Cancer Patients

Yildiz İ., Varol U., Alacacioglu A.

JOURNAL OF BREAST HEALTH , cilt.10, sa.4, ss.216-221, 2014 (ESCI) Sürdürülebilir Kalkınma

51. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.

Yildiz İ., Ekenel M., Akman T., Kocar M., Uysal M., Kanitez M., et al.

Anticancer research , cilt.34, sa.8, ss.4329-34, 2014 (SCI-Expanded, Scopus)

52. The behavior of Turkish cancer patients in fasting during the holy month of Ramadan.

TAŞ F., KARABULUT S., Ciftci R., YILDIZ İ., Keskin S., Kilic L., et al.

Japanese journal of clinical oncology , cilt.44, sa.8, ss.705-10, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

53. High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer.

Ciftci R., TAŞ F., TİLGEN YASASEVER C., Aksit E., KARABULUT S., Sen F., et al.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine , cilt.35, sa.7, ss.6941-8, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

54. Sexual satisfaction, anxiety, depression and quality of life in testicular cancer survivors

Alacacioglu A., Ulger E., Varol U., YAVUZŞEN T., Akyol M., Yildiz Y., et al.

MEDICAL ONCOLOGY , cilt.31, sa.7, 2014 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

55. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer

Varol U., Yildiz İ., Salman T., KARABULUT B., Uslu R.

TUMORI J , cilt.100, sa.4, ss.370-376, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

56. Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey.

Yildiz İ., Sen F., Ekenel M., Darendeliler E., Bavbek S., Agaoglu F., et al.

In vivo (Athens, Greece) , cilt.28, sa.3, ss.403-9, 2014 (SCI-Expanded, Scopus)

57. Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?

Karabulut S., Aksit E., Tas F., Ciftci R., Aydiner A., Yildiz İ., et al.

TUMOR BIOLOGY , cilt.35, sa.5, ss.4323-4329, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

58. Isolated Liver Metastasis of Sacrococcygeal Chordoma: Case Report and Review of the Literature

Akyol M., Varol U., Yildiz İ., Bayoglu I. V., Yildiz Y., Demir L., et al.

CASE REPORTS IN ONCOLOGICAL MEDICINE , cilt.2014, 2014 (ESCI)

59. Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.

YILDIZ İ., Sen F., Kilic L., Ciftci R., BAŞARAN M.

Korean journal of urology , cilt.55, sa.1, ss.74-6, 2014 (Hakemli Dergi)

60. Quality-of-Life in Turkish Cancer Patients: The Impact of Sociodemographic Characteristics, Medical History, and Management

Toptas T., Yildiz İ., YILDIZ M., Varol U., Bayoglu I. V., Ozguroglip M.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.1, ss.23-29, 2014 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

61. Survival Analysis of Triple Negative and Her2 Positive Breast Cancer Patients: Single Center Report

Varol U., ÇAKAR B., Yildiz İ., TUNAKAN DALGIÇ C., ÖZIŞIK H., Ozisik M., et al.

JOURNAL OF BREAST HEALTH , cilt.10, sa.1, ss.42-46, 2014 (Hakemli Dergi) Sürdürülebilir Kalkınma

62. Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer

Bayoglu I. V., Varol U., Yildiz İ., Muslu U., Alacacioglu A., Kucukzeybek Y., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.17, ss.7119-7123, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

63. First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer

Varol U., Dirican A., Yildiz İ., Oktay E., Degirmenci M., Alacacioglu A., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.7, ss.3157-3161, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

64. Depression, Anxiety and Sexual Satisfaction in Breast Cancer Patients and their Partners-Izmir Oncology Group Study

Alacacioglu A., Ulger E., Varol U., Yildiz İ., Salman T., Bayoglu V., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.24, ss.10631-10636, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

65. A case of non-Hodgkin lymphoma coexisting with both hepatitis B and tuberculosis

Yildiz İ., Varol U., Varol Y., BAŞARAN M.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.29, sa.2, ss.53-56, 2014 (ESCI, Scopus) Sürdürülebilir Kalkınma

66. Anticancer Therapy for Breast Cancer Patients with Skin Metastases Refractory to Conventional Treatments

Varol U., Yildiz İ., Alacacioglu A., Uslu R.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.4, ss.1885-1887, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

67. Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma

Yildiz İ., Sen F., Kilic L., Ekenel M., Ordu C., Kilicaslan I., et al.

CURRENT ONCOLOGY , cilt.20, sa.6, 2013 (SCI-Expanded, Scopus)

68. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma

TAŞ F., KARABULUT S., Bilgin E., Sen F., YILDIZ İ., TAŞTEKİN D., et al.

TUMOR BIOLOGY , cilt.34, sa.6, ss.3529-3536, 2013 (SCI-Expanded, Scopus)

69. The Role of Surgical Methods in the Treatment of Anorectal Malignant Melanoma (AMM)

Keskin S., Tas F., Karabulut S., Yildiz İ., Kilic L., Ciftci R., et al.

ACTA CHIRURGICA BELGICA , cilt.113, sa.6, ss.429-433, 2013 (SCI-Expanded, Scopus)

70. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer.

TAŞ F., Sen F., Odabas H., Kilic L., Keskin S., YILDIZ İ.

International journal of clinical oncology , cilt.18, sa.5, ss.839-46, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

71. Clinical significance of serum M30 and M65 levels in melanoma

TAŞ F., KARABULUT S., SERİLMEZ M., YILDIZ İ., Sen F., Ciftci R., et al.

MELANOMA RESEARCH , cilt.23, sa.5, ss.390-395, 2013 (SCI-Expanded, Scopus)

72. Serum M65 as a biomarker for metastatic renal cell carcinoma.

YILDIZ İ., Sen F., Kilic L., Keskin S., DURANYILDIZ H. D., Bilgin E., et al.

Clinical genitourinary cancer , cilt.11, sa.3, ss.290-6, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

73. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer

Yildiz İ., Tas F., Kilic L., Sen F., Saip P., Eralp Y., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.72, sa.2, ss.437-444, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

74. Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naive non-small cell lung cancer

Keskin S., TAŞ F., EKENEL M., Kilic L., Sen F., YILDIZ İ., et al.

TUMORI , cilt.99, sa.4, ss.463-468, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

75. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival.

TAŞ F., Sen F., Keskin S., Kilic L., YILDIZ İ.

Molecular and clinical oncology , cilt.1, sa.4, ss.788-792, 2013 (Hakemli Dergi) Sürdürülebilir Kalkınma

76. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.

Sen F., Yildiz İ., Başaran M., Ekenel M., Oz F., Kilic L., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.18, sa.3, ss.775-81, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

77. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).

Keskin S., YILDIZ İ., AYDOĞMUŞ ŞEN F., AYDOĞAN F., Kilic L., EKENEL M., et al.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico , cilt.15, sa.5, ss.403-8, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

78. Patterns of Complementary and Alternative Medicine Use among Turkish Cancer Patients

YILDIZ İ., Ozguroglu M., TOPTAŞ T., TURNA Z. H., Sen F., YILDIZ M.

JOURNAL OF PALLIATIVE MEDICINE , cilt.16, sa.4, ss.383-390, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

79. Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.

Aydiner A., Kilic L., Yildiz İ., Keskin S., Sen F., Kucucuk S., et al.

Medical oncology (Northwood, London, England) , cilt.30, sa.1, ss.354, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

80. Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer.

TAŞ F., Kilic L., Bilgin E., Keskin S., Sen F., Ciftci R., et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society , cilt.23, sa.2, ss.276-81, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

81. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.

Aykan N. F., Yildiz İ., Sen F., Kilic L., Keskin S., Ciftci R., et al.

Medical oncology (Northwood, London, England) , cilt.30, sa.3, ss.679, 2013 (SCI-Expanded, Scopus)

82. Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status

Aydiner A., Yildiz İ., Seyidova A.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.14, sa.5, ss.3255-3261, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

83. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?

Kilic L., Ordu C., EKENEL M., YILDIZ İ., Keskin S., Sen F., et al.

Medical oncology (Northwood, London, England) , cilt.30, sa.3, ss.660, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

84. Clinical and prognostic significance of coagulation assays in melanoma.

TAŞ F., Ciftci R., Kilic L., Bilgin E., Keskin S., Sen F., et al.

Melanoma research , cilt.22, sa.5, ss.368-75, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

85. Primary Burkitt's Lymphoma Presenting as a Rapidly Growing Thyroid Mass

YILDIZ İ., Sen F., Toz B., Kilic L., Agan M., BAŞARAN M.

CASE REPORTS IN ONCOLOGY , cilt.5, sa.2, ss.388-393, 2012 (ESCI, Scopus)

86. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.

Yildiz İ., Sen F., Basaran M., Ekenel M., Agaoglu F., Darendeliler E., et al.

Japanese journal of clinical oncology , cilt.41, sa.12, ss.1380-7, 2011 (SCI-Expanded, Scopus)

87. Frequency of cardiovascular events in patients with metastatic renal cell carcinoma under sunitinib treatment.

Yildiz İ., Sen F., BAŞARAN M., Bavbek S. E.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)

88. Triplet chemotherapy combination with gemcitabine, cisplatin, and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer

TAŞ F., Sen F., Guney N., Yildiz İ., Camlica H., Keskin S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

89. Triplet chemotherapy combination with gemcitabine, cisplatin, and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer

TAŞ F., Sen F., Guney N., Yildiz İ., Camlica H., Keskin S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)

90. Impaired coronary flow reserve in patients with metastatic cancer treated with sunitinib.

Sen F., Yildiz İ., Oflaz H., Oz F., Kilic L., Gurdal A., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)

91. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.

TAŞ F., Keskin S., Karadeniz A., Dagoglu N., Sen F., Kilic L., et al.

Oncology , cilt.81, sa.5-6, ss.353-8, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

92. Optic disc and choroidal metastasis from sporadic medullary thyroid carcinoma: case report and review of the literature.

Yildiz İ., Sen F., Tuncer S., Kilic L., Basaran M., Bavbek S.

Onkologie , cilt.34, sa.11, ss.630-3, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

93. An unusual case of recurrent non-Hodgkin's lymphoma presented with massive ascites, peritoneal involvement and elevated CA-125 level

Doventas A., YILDIZ İ., TOPTAŞ T., Baslar Z., Bilici A., ERDİNÇLER Ü. D.

JOURNAL OF BUON , cilt.14, sa.2, ss.324-325, 2009 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 22

1. The professional seniority affects the clinical application of total neoadjuvant therapy for locally advanced rectal cancer.

Tasci E. S., AYTAÇ E., Ajredini M., Mutlu A. U., Yildiz İ., Ozer L.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri)

2. The prognostic impact of intramural invasion in patients undergoing surgery for non-metastatic colon cancer.

Ozer L., Tasci E. S., Mutlu A. U., Piyade B., Ramoglu N., Ajredini M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri)

3. Clinicopathological and prognostic significance of microsatellit instability (MSI) status and PDI-1 expression in Turkish patients with gastric cancer.

Yildiz İ., Bahsi S., Erdamar S., Goksel S., Demir G., Er Ö., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) Sürdürülebilir Kalkınma

4. Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib

Neiman V., Keizman D., Sarid D., Lee J., Sella A., Gottfried M., et al.

41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27, (Özet Bildiri)

5. Sexual satisfaction, anxiety, depression and quality of life amoung Turkish gynecological cancer patients

Yildiz Y., Akyol M., Alacacioglu A., Kucukzeybek Y., Asik N., Taskaynatan H., et al.

41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27, (Özet Bildiri)

6. Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer.

Salman T., Bilici A., Arslan C., Varol U., Yildiz İ., Akyol M., et al.

Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 21 - 23 Ocak 2016, cilt.34, (Özet Bildiri) Sürdürülebilir Kalkınma

7. Evaluation of c-kit (CD 117) expression as a prognostic factor in testicular germ cell tumors: An Izmir Oncology Group (IZOG) study.

Salman T., Yildiz E., Yildiz İ., Yavuzer D., Unlu M., Varol U., et al.

Genitourinary Cancers Symposium, San-Francisco, Kostarika, 7 - 09 Ocak 2016, cilt.34, (Özet Bildiri)

8. The effects of adjuvant endocrine treatment on the serum leptin, adiponectin and body composition in patients with breast cancer [Izmir Oncology Group(IZOG) Study]

Akyol M., Demir L., Alacacioglu A., Ellidiokuz H., Kucukzeybekl Y., Yildiz Y., et al.

European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51, (Özet Bildiri)

9. First-line cisplatin plus bolus 5-Fluorouracil combination in patients with locally advanced and metastatic esophageal cancer

Akyol M., Kucukzeybek Y., Varol U., Yildiz İ., Cokmert S., Bayoglu I. V., et al.

ESMO 17th World Congress on Gastrointestinal Cancer, Barcelona, İspanya, 1 - 04 Temmuz 2015, cilt.26, (Özet Bildiri) Sürdürülebilir Kalkınma

10. Can basal neutrophil/lymphocytes ratio predict clinical outcome of melanoma patients?

Bayoglu I. V., Kurtel G., Alacacioglu A., Varim C., Yildiz İ., Kucukzeybek Y., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)

11. Patients (pts) with metastatic chromophobe renal cell carcinoma (mchRCC) treated with sunitinib (Su) therapy (tx): Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC)

Yildiz İ., Sarid D., Lee J., Chish A., Sella A., Gottfried M., et al.

12. Patients with metastatic chromophobe renal cell carcinoma treated with sunitinib therapy: Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC).

Keizman D., Sarid D., Lee J., Gottfried M., Maimon N., Hammers H. J., et al.

Genitourinary Cancers Symposium, Florida, Amerika Birleşik Devletleri, 26 - 28 Şubat 2015, cilt.33, (Özet Bildiri)

13. Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer.

Ciftci R., TAŞ F., Aksit E., VATANSEVER S., KARABULUT S., Sen F., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

14. Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial.

Yildiz İ., EKENEL M., Altman T., Kocar M., Uysal M., Kanitez M., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)

15. Clinical significance of serum protein and mRNA level of insulin-like growth factor-1 (IGF-1) in patients with hepatocellular carcinoma

KARABULUT S., Aykan N. F., Yildiz İ., Kilic L., Sen F., VATANSEVER S.

Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 16 - 18 Ocak 2014, cilt.32, (Özet Bildiri)

16. Comparison of mucosal and cutaneous melanoma in the head and neck region: Different clinical features and similar outcomes.

Ciftci R., Keskin S., KARABULUT S., Yildiz İ., Kilic L., Sen F., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)

17. Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy

Yildiz İ., Sen F., Kilic L., Keskin S., Ciftci R., EKENEL M., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma

18. Coagulation assays in breast cancer: Correlation of plasma D-dimer with tumor load and invasiveness in breast cancer patients.

KARABULUT S., Kilic L., Ciftci R., Yildiz İ., Sen F., Keskin S., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma

19. Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib?

BAŞARAN M., Yildiz İ., Sen F., Kilic L., Keskin S., Darendeliler E., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)